IL-10、IL-17在子宫内膜癌中的表达及意义

目的 探讨白细胞介素 （IL）-10、IL-17在子宫内膜癌中的表达及其与子宫内膜癌发生发展的关系。 方法 采用酶联免疫吸附法检测15例子宫内膜癌、15例良性子宫疾病患者外周静脉血清中IL-10、IL-17的表达，链霉亲和素-生物素-过氧化物酶复合物 (SABC）免疫组织化学 （IHC）染色法分别检测两组标本组织中IL-10、IL-17的表达，IPP 6.0图像分析软件计算目的蛋白的积分光密度 （IOD）值，并结合临床病理资料进行分析。 结果 子宫内膜癌患者血清IL-10水平及组织IL-10的IOD值均高于良性子宫疾病患者 （P<0.05）；子宫内膜癌患者的血清IL-17水平及组织IL-17 IOD值与良性子宫疾病患者相比差异无统计学意义；子宫内膜癌患者血清IL-10水平在ⅠB~Ⅱ期、G2~G3级、有肌层浸润、有脉管癌栓者高于ⅠA期、G1级、无肌层浸润、无脉管癌栓者 （P<0.05），各组织类型间差异无统计学意义； 子宫内膜癌患者血清IL-17水平在ⅠB~Ⅱ期、有肌层浸润、有脉管癌栓者低于ⅠA期、无肌层浸润、无脉管癌栓者 （P<0.05），在细胞分级、组织类型方面差异无统计学意义。结论 IL-10的过表达参与子宫内膜癌的发生发展，抑制IL-10的表达可能解除机体对肿瘤的免疫耐受；IL-17的低表达参与子宫内膜癌的进展，促进IL-17的表达可能增强机体的抗肿瘤反应。

Expression and Clinical Signification of IL-10 and IL-17 in Endometrial Cancer

Objective To explore the expression of IL-10 and IL-17 in endometrial cancer and their relationships with tumor progression. Methods The sera levels of IL-10 and IL-17 were detected by enzyme-linked immune-sorbent assay in 15 benign hysterectomies and 15 endometrial cancers, the expressions of IL-10 and IL-17 in the tissue were measured by immunohistochemistry assay (SABC) with the evaluation of IOD value, clinic-pathological characteristics were retrieved and analyzed. Results Both sera expression and tissue IOD value of IL-10 were significantly higher in endometrial cancer than those in benign uterine, while no difference was found in IL-17 between the two groups. Sera IL-10 of ⅠB-Ⅱ stage, G2-G3, with myoinvasion, with vas tumor emboli was higher than that of ⅠA stage, G1, without myoinvasion, and without vas tumor emboli, while no difference was found among tissue types. Sera IL-17 of ⅠB-Ⅱ stage, with myoinvasion, with vas tumor emboli was lower than that of IA stage, without myoinvasion, and without vas tumor emboli, while no difference was found among tumor grades nor tissue types. Conclusion High expression of IL-10 may participate in the genesis and development of uterine endometrial cancer, while low expression of IL-17 may participate in its development.